It is reported here that Fisetin treatment could decline the enhanced level of both TNFα and IL1α (Figure 5), which is consistent with recovery in SOD1 activity (Figure 3), declined ROS level (Figure 2(a)), and HCC regression (Figure 1). This evidence concerns the gene SOD1 and hepatocellular carcinoma.